IPHA - Innate Pharma SA

-

$undefined

N/A

(N/A)

Innate Pharma SA NasdaqGS:IPHA Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Location: 117, Avenue de Luminy, Bp 30191, Marseille, 13009, France | Website: https://www.innate-pharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

153M

Cash

80.77M

Avg Qtr Burn

-1.724M

Short % of Float

0.11%

Insider Ownership

0.00%

Institutional Own.

0.24%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LUMOXITI Details
Leukemia, Cancer

Approved

Quarterly sales

Monalizumab + durvalumab + oleclumab Details
Non-small cell lung carcinoma, Cancer, Solid tumor/s

Phase 3

Update

IPH6101 / SAR443579 Details
Cancer, Relapsed/refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia

Phase 2

Data readout

Phase 2

Data readout

IPH5201 Details
Lung cancer, Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

Lacutamab (IPH4102) + GEMOX Details
Cancer, Lymphoma, Peripheral T cell cancer

Phase 2

Data readout

Avdoralimab (IPH5401) Details
COVID-19, Infectious disease

Phase 2

Update

Lacutamab (IPH4102) Details
Lymphoma, Cancer, Mycosis fungoides

Phase 2

Update

Lacutamab (IPH4102) Details
Lymphoma, Sezary syndrome, Cancer

Phase 2

Update

IPH6401 / SAR’514 Details
Cancer, relapsed or refractory light chain amyloidosis, Multiple myeloma, Post-stroke recovery

Phase 1/2

Data readout

IPH6501 Details
Cancer, Non-Hodgkin lymphoma

Phase 1/2

Update

Lacutamab (IPH4102) Details
Cancer, Lymphoma, Peripheral T cell cancer

Phase 1b

Data readout

IPH4502 Details
Cancer, Solid tumor/s

Phase 1

Data readout

IPH5301 (anti-CD73) Details
Cancer, Solid tumor/s

Phase 1

Data readout

Monalizumab (anti-NKG2A) Details
Head and neck cancer, Head and neck squamous cell carcinoma, Cancer

Failed

Discontinued

Avdoralimab (IPH5401) Details
Bullous pemphigoid , Skin disease/disorder

Failed

Discontinued